4,757 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Bought by DRW Securities LLC

DRW Securities LLC acquired a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,757 shares of the medical research company’s stock, valued at approximately $1,592,000.

Other institutional investors also recently modified their holdings of the company. Van ECK Associates Corp bought a new stake in Bio-Rad Laboratories during the second quarter valued at $180,040,000. First Eagle Investment Management LLC boosted its position in Bio-Rad Laboratories by 32,296.9% during the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock valued at $173,773,000 after acquiring an additional 634,311 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Bio-Rad Laboratories by 64.4% during the second quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company’s stock valued at $135,081,000 after acquiring an additional 193,700 shares during the last quarter. Select Equity Group L.P. boosted its position in Bio-Rad Laboratories by 26.2% during the second quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company’s stock valued at $177,391,000 after acquiring an additional 134,856 shares during the last quarter. Finally, Earnest Partners LLC boosted its position in Bio-Rad Laboratories by 17.8% during the second quarter. Earnest Partners LLC now owns 606,788 shares of the medical research company’s stock valued at $165,720,000 after acquiring an additional 91,882 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Up 1.0 %

BIO opened at $336.09 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. Bio-Rad Laboratories, Inc. has a fifty-two week low of $262.12 and a fifty-two week high of $387.99. The firm has a market capitalization of $9.41 billion, a PE ratio of -12.30 and a beta of 0.93. The company’s 50-day moving average is $340.63 and its 200 day moving average is $316.68.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company had revenue of $649.70 million for the quarter, compared to analyst estimates of $628.18 million. During the same quarter in the prior year, the business posted $2.33 EPS. The firm’s revenue was up 2.8% compared to the same quarter last year. As a group, research analysts predict that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BIO. Citigroup upped their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price objective on the stock. Royal Bank of Canada increased their price objective on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and an average target price of $391.80.

Insider Buying and Selling

In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. This trade represents a 28.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP James Barry sold 623 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company’s stock, valued at approximately $48,582.03. This trade represents a 80.91 % decrease in their position. The disclosure for this sale can be found here. 17.50% of the stock is currently owned by company insiders.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.